GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.
DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its longest-lasting sensor technology to date.
AbbVie (NYSE:ABBV) secured exclusive global rights to a novel cancer-fighting antibody from RemeGen Co. on Monday, marking one of the year’s largest oncology licensing agreements as the pharmaceutical giant moves to integrate next-generation bispecifics with its expanding "ADC" platform.
Shake Shack (NYSE:SHAK) signaled a period of aggressive expansion and improving profitability, issuing an upbeat 2026 outlook that highlights its evolution from a cult favorite to a dominant global restaurant platform.
GTCR announced the completion of its $24.25 billion sale of Worldpay to Global Payments (NYSE:GPN) on Monday, marking the conclusion of a complex three-way transaction that reshapes the landscape of the global payments industry.
SOPHiA GENETICS (NASDAQ:SOPH) reported a record-breaking performance for 2025, driven by a surge in demand for its AI-powered genomic analysis, as the company prepares for a major leadership transition and moves closer to profitability.
Viking Therapeutics (NASDAQ:VKTX) shares were in focus Monday after the company announced the peer-reviewed publication of its Phase 2 VENTURE study results, reinforcing the weight-loss potential of its lead candidate as it enters a pivotal year of Phase 3 testing.
OneSpaWorld Holdings Limited (NASDAQ:OSW) projected its annual revenue will surpass the $1 billion mark for the first time in 2026, as the company streamlines its global operations to capitalize on a record-breaking surge in cruise ship travel.
J.Jill (NYSE:JILL) raised its fourth-quarter and full-year financial guidance on Monday, citing a "stronger-than-anticipated" conclusion to the 2025 holiday season as the retailer prepares for key investor meetings at the ICR Conference.
Zura Bio Limited 9NASDAQ:ZURA) announced it is expanding the patient population for its mid-stage trial of tibulizumab in hidradenitis suppurativa (HS), a move intended to bolster the study’s statistical power as the company prepares for a critical data readout later this year.
Aura Minerals (NASDAQ:AUGO) reported record-breaking preliminary production for the fourth quarter of 2025, bolstered by the successful ramp-up of its Borborema mine and the initial integration of its newest acquisition in Brazil.
Lululemon Athletica (NASDAQ:LULU) raised its fourth-quarter profit and revenue forecasts, signaling that resilient holiday demand for its yoga-inspired apparel is helping the company navigate a cooling U.S. retail environment.
